Showing results (71-80 of 324) with videos related to

Sort By:
Pageof 33
Journal of Geriatric Oncology|September 24, 2014
Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosisChia-Lin Hsu, Jen-Hau Chen, Kuan-Yu Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2014
Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysisSanjay Popat, Tony Mok, James Chih-Hsin Yang, et al.
BMC Cancer|October 11, 2011
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancerYi-Long Wu, Keunchil Park, Ross A Soo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2022
Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)James Chih-Hsin Yang, Yuichiro Ohe, Chao-Hua Chiu, et al.
The Lancet. Oncology|November 3, 2009
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009Ross A Soo, Benjamin O Anderson, Byoung Chul Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung CancerPei Ni Ding, Sarah J Lord, Val Gebski, et al.
Journal of Nanobiotechnology|August 21, 2019
Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptidesShu-Ting Hong, Huaching Lin, Chen-Shen Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancerYen-Ting Lin, Yu-Fen Wang, James Chih-Hsin Yang, et al.
Targeted Oncology|February 7, 2019
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid TumorsToshihiko Doi, James Chih-Hsin Yang, Kohei Shitara, et al.
Anticancer Research|January 30, 2003
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracilChih-Hung Hsu, Ann-Lii Cheng, Chiun Hsu, et al.
Pageof 33